Suggested remit: To appraise the clinical and cost effectiveness of pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6397
Provisional Schedule
- Committee meeting:
- 06 October 2026
- Expected publication:
- 24 February 2027
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
Stakeholders
- Companies sponsors
- Eli Lilly (pirtobrutinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- African Caribbean Leukaemia Trust
- Anthony Nolan
- Black Health Agency for Equality
- Blood Cancer UK
- Cancer Black Care
- Cancer52
- Chronic Lymphocytic Leukaemia Support Association
- Independent Cancer Patients Voice
- Kevin Kararwa Leukaemia Trust
- Leukaemia Cancer Society
- Leukaemia Care
- Leukaemia UK
- Lymphoma Action
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- WMUK
- Professional groups
- Association of Cancer Physicians
- British Geriatrics Society
- British Institute of Radiology
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Society for Haematology
- British Society of Interventional Radiology
- Cancer Research UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK CLL Forum
- UK Cutaneous Lymphoma Group
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- AbbVie (venetoclax)
- AstraZeneca UK (acalabrutinib)
- BeOne Medicines UK (zanubrutinib)
- Johnson & Johnson Innovative Medicine (ibrutinib)
- Roche (obinutuzumab, rituximab)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Cell and Gene Therapy Catapult
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Cochrane Haematology Group
- Genomics England
- Institute of Cancer Research
- Leukaemia Busters
- Lymphoma Research Trust
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 March 2026 | Invitation to participate |
| 14 January 2026 - 11 February 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 14 October 2024 | Note - Note added to the project documents |
| 08 August 2024 | Note - Note added to the project documents |
| 14 February 2024 | In progress. Scoping commenced. |
| 30 January 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 30 January 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual